-
Add to Cart The item has been addedAb175523-10mgElezanumab (anti-RGMA) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab (anti-RGMA) potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. -
Add to Cart The item has been addedAb175523-1mgElezanumab (anti-RGMA) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab (anti-RGMA) potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. -
Add to Cart The item has been addedAb175523-5mgElezanumab (anti-RGMA) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab (anti-RGMA) potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. -
Add to Cart The item has been addedAb170880-100μgEmibetuzumab (anti-MET) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab (anti-MET) shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and -
Add to Cart The item has been addedAb170880-10mgEmibetuzumab (anti-MET) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab (anti-MET) shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and -
Add to Cart The item has been addedAb170880-1mgEmibetuzumab (anti-MET) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab (anti-MET) shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and -
Add to Cart The item has been addedAb170880-5mgEmibetuzumab (anti-MET) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab (anti-MET) shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and -
Add to Cart The item has been addedAb176561-100μgFeladilimab (anti-ICOS) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab (anti-ICOS) binds to ICOS-expressing T cells. Feladilimab (anti-ICOS) has the potential for the research of cancer.Purity>95% (SDS-PAGE&SEC)Endotoxin -
Add to Cart The item has been addedAb176561-10mgFeladilimab (anti-ICOS) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab (anti-ICOS) binds to ICOS-expressing T cells. Feladilimab (anti-ICOS) has the potential for the research of cancer.Purity>95% (SDS-PAGE&SEC)Endotoxin -
Add to Cart The item has been addedAb176561-1mgFeladilimab (anti-ICOS) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab (anti-ICOS) binds to ICOS-expressing T cells. Feladilimab (anti-ICOS) has the potential for the research of cancer.Purity>95% (SDS-PAGE&SEC)Endotoxin -
Add to Cart The item has been addedAb176561-5mgFeladilimab (anti-ICOS) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab (anti-ICOS) binds to ICOS-expressing T cells. Feladilimab (anti-ICOS) has the potential for the research of cancer.Purity>95% (SDS-PAGE&SEC)Endotoxin -
Add to Cart The item has been addedAb176073-100μgFlanvotumab (anti-TYRP1) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab (anti-TYRP1) acts function via natural killing-mediated antibody-dependent
